Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMDTC in Participants With Solid Tumors Who Have Cisplatin-Induced Renal Insufficiency
NCT07824843Phase 1Not yet recruiting
- Sponsor
- Jianersheng Pharmaceutical Technology
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gmdtc in cisplatin-induced nephrotoxicity (CIN), sponsored by Jianersheng Pharmaceutical Technology. Primary endpoints: Adverse Events up to 90 days, Dose-Limiting Toxicity and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
gmdtc
03
Conditions
cisplatin-induced nephrotoxicity (CIN)
Beyond the preview
Go deeper on NCT07824843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07824843.